Research on the Prognostic Role of Vascular Endothelial Growth Factor in Renal Cell Carcinoma | Chapter 8 | Highlights on Medicine and Medical Research Vol. 7

 Renal cell carcinoma is the most deadly type of urological cancer. 60% to 70% of RCCs are localised instances for which nephrectomy is the gold standard treatment. At the time of diagnosis, 20% of cases are progressed. Due to their chemo- and radio-resistance, the treatment plan for such individuals remains inadequate. In renal malignancies, Vascular Endothelial Growth Factor is a significant modulator of angiogenesis. Hypoxia Inducible Factor-1 is produced when the von Hippel-Lindau gene is inactivated. Following this, VEGF-A levels in the cancer tissue skyrocket. This promotes distant metastasis, uncontrolled development, and apoptosis resistance, resulting in tumour creation. As a result, targeting VEGF may be useful in the therapy of RCC.

Methods and Materials: A total of 150 tissue blocks from histopathologically confirmed RCC patients were used in this study. The ethical clearance was provided by the Sri Ramachandra Institute of Higher Education & Research (Deemed University) Ethics Committee. The Biotin Streptavidin Immunoperoxidase technique was used to examine VEGF. The scoring for Q has been completed.

Statistical Analysis: The Chi square test and Fischer Exact test were used to evaluate the relationship between VEGF expression in tumour cells and histology, grade, and stage. The statistical package SPSS (version 20.0) was used. P values of less than 0.05 were considered significant.

The goal of this study was to look at the expression of Vascular Endothelial Growth Factor in Renal Cell Carcinoma cases and see if it might be used as a biomarker. Results: In the tumour location, 96.6 percent of RCC cases were VEGF positive, although cells in the nearby normal tissue area showed poor staining. In RCC, tumour angiogenesis has been found to be a major predictor of prognosis.

Conclusion: VEGF inhibition can normalise permeability, increase host immunity, and increase access to therapies like chemotherapy.

Author(s) Details

Deepika Chandrasekaran
Department of Physiology, Sri Ramachandra Institute of Higher Education and Research, Chennai, India.

R. Padmavathi
Department of Physiology, Sri Ramachandra Institute of Higher Education and Research, Chennai, India.

Sandhya Sundaram
Department of Pathology, Sri Ramachandra Institute of Higher Education and Research, Chennai, India.

N. Kathiresan
Department of Surgical Oncology, Apollo Speciality Hospital, Chennai, India.

View Book :- https://stm.bookpi.org/HMMR-V7/article/view/1063